JB Global approves sale of JAT's Neurio range

By Justin Ware. Published at Jul 4, 2018, in Juniors

Jat Energy (ASX:JAT) has informed the market today that JD Global, China’s largest retailer by revenue, has approved the sale of Sunnya’s Neurio branded products.

The Neurio range will be sold to Chinese consumers on JD Global’s cross border and supermarket platforms: www.JD.com and www.JD.hk.

JD has placed orders on the following products:

  • Neurio – Lactoferrin milk powder, and
  • Neurio – DHA Algae oil softgel

JD services more than 266 million annual active users, and claims to possess the largest fulfilment infrastructure of any e-commerce company in China. Covering 2,380 counties and districts, JD has seven fulfilment centres and more than 400 warehouses.

Lactoferrin is a natural antibacterial agent, found in mammalian milk, tears and saliva.

Overall this is an early stage play and as such any investment decision should be made with caution and professional financial advice should be sought.

JAT Executive Director Wilton Yao spoke on the development, “We continue to receive positive responses to Neurio products, from everyone we talk to. I have high expectations for this brand. Buyers are impressed with its immune system boost.”

As previously announced, JAT has agreed to purchase 51% of Sunnya Pty Limited, subject to shareholder approval. The Neurio range are products supplied by Sunnya Pty Limited.

Sunnya has agreed to supply JAT the entirety of the Neurio product required to fulfil the JD agreement over the next 12 months, regardless of whether the Sunnya acquisition proceeds.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.